Education
About Us
Working with TipRanks
Follow Us
Bactiguard Holding AB (SE:BACTI.B)
:BACTI.B
Top Page
Bactiguard Holding AB
(Frankfurt:BACTI.B)
45Neutral
Bactiguard Holding AB (BACTI.B) vs. S&P 500 (SPY)
Market Cap
kr1.03B
Dividend YieldN/A
Average Volume (3M)4.55K
Price to Earnings (P/E)―
Beta (1Y)0.28
Revenue Growth19.91%
EPS Growth78.46%
CountrySE
Employees199
SectorHealthcare
Sector Strength64
IndustryMedical Equipment & Supplies
Share Statistics
EPS (TTM)-0.85
Shares Outstanding31,043,884
10 Day Avg. Volume7,453
30 Day Avg. Volume4,552
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr29.81Price Target Upside-1.31% Downside
Rating ConsensusHold
Number of Analyst Covering1
Bactiguard Holding AB Business Overview & Revenue Model
Company DescriptionBactiguard Holding AB is a Swedish medical technology company that specializes in infection prevention solutions. The company operates primarily within the healthcare sector, providing innovative products designed to reduce the risk of healthcare-associated infections. Bactiguard's core offerings include its proprietary coating technology, which is applied to medical devices such as catheters and implants to minimize bacterial adhesion and biofilm formation, effectively lowering the incidence of infections.
How the Company Makes MoneyBactiguard Holding AB generates revenue through the production and licensing of its infection prevention technologies. The company's primary revenue streams include direct sales of coated medical devices and licensing agreements with other medical device manufacturers who integrate Bactiguard's coating technology into their products. Significant partnerships with global medical technology companies also play a crucial role in driving sales and expanding market reach. The company benefits from a growing demand for infection control solutions in healthcare settings, which is a key factor contributing to its earnings.
Bactiguard Holding AB Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 261.88M | 203.99M | 223.56M | 169.49M | 172.31M | Gross Profit |
| 225.91M | 139.98M | 180.14M | 130.80M | 137.12M | EBIT |
| -28.86M | -131.93M | -54.23M | -51.19M | -21.85M | EBITDA |
| 25.86M | -89.98M | -543.00K | -5.94M | 9.21M | Net Income Common Stockholders |
| -29.82M | -138.38M | -52.88M | -58.77M | -38.39M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 116.73M | 123.22M | 197.73M | 217.59M | 9.89M | Total Assets |
| 655.91M | 662.17M | 807.70M | 849.29M | 675.22M | Total Debt |
| 227.77M | 233.10M | 238.70M | 247.96M | 264.02M | Net Debt |
| 111.04M | 109.88M | 40.97M | 30.37M | 254.14M | Total Liabilities |
| 327.57M | 309.00M | 311.99M | 307.84M | 301.87M | Stockholders Equity |
| 328.34M | 353.18M | 495.71M | 541.45M | 373.35M |
| Cash Flow | Free Cash Flow | |||
| 10.21M | -60.94M | -7.86M | -38.00K | -14.65M | Operating Cash Flow |
| 24.99M | -52.33M | 3.06M | 7.26M | 702.00K | Investing Cash Flow |
| -14.78M | -8.61M | -10.92M | -7.29M | -57.01M | Financing Cash Flow |
| -21.20M | -11.84M | -13.89M | 205.83M | 46.20M |
Bactiguard Holding AB Technical Analysis
Negative
30.20
Price Trends
31.38
Negative
33.42
Negative
44.79
Negative
Market Momentum
-0.20
Negative
49.83
Neutral
25.32
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:BACTI.B, the sentiment is Negative. The current price of 30.2 is above the 20-day moving average (MA) of 29.84, below the 50-day MA of 31.38, and below the 200-day MA of 44.79, indicating a neutral trend. The MACD of -0.20 indicates Negative momentum. The RSI at 49.83 is Neutral, neither overbought nor oversold. The STOCH value of 25.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:BACTI.B.
Bactiguard Holding AB Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | kr997.81M | 17.66 | 18.74% | ― | 10.46% | 22.82% | |
51 Neutral | kr502.43M | ― | -12.29% | ― | 6.11% | -553.72% | |
51 Neutral | $5.20B | 3.26 | -40.34% | 2.93% | 17.68% | 1.94% | |
46 Neutral | €826.48M | ― | -1.05% | ― | 16.17% | 82.09% | |
46 Neutral | kr417.59M | ― | -33.80% | ― | 72.05% | 33.68% | |
45 Neutral | kr1.03B | ― | -8.64% | ― | 19.91% | 78.46% | |
44 Neutral | €285.45M | ― | -12.79% | ― | -6.43% | -323.52% |
* Healthcare Sector Average
Performance Comparison
SE:BACTI.B
Bactiguard Holding AB
30.20
-38.40
-55.98%
SE:CRAD.B
C-Rad AB Class B
29.45
-9.00
-23.41%
SE:INTEG.B
Integrum AB Class B
13.46
-37.94
-73.81%
SE:MNTC
Mentice AB
20.20
-16.20
-44.51%
SE:SEDANA
Sedana Medical AB
10.72
-8.20
-43.34%
SE:BRAIN
BrainCool AB
1.70
-0.27
-13.79%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.